Recruiting
Adipose Tissue Storage in the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery
The present protocol aims to understand and establish whether there is a causal link between adipose tissue metabolic remodeling and Type 2 Diabetes (T2D) remission after bariatric surgery. All participants will have a bariatric surgery, divided in 2 groups: with or without T2D.
ClinicalTrials.gov IDNCT05934409
PhaseNA
Enrollment40
SponsorUniversité de Sherbrooke
Age18 Years and older
SexALL
Conditions studied
Diabetes Mellitus Type 2
About this study
The present protocol aims to understand and establish whether there is a causal link between adipose tissue metabolic remodeling and Type 2 Diabetes (T2D) remission after bariatric surgery. All participants will have a bariatric surgery, divided in 2 groups: with or without T2D.
Interventions
- Procedure: Bariatric surgery — Laparoscopic Sleeve Gastrectomy
- Drug: Nicotinic Acid — Only during A1. 150mg every half hour for 6 hours. A total dose of 1800mg will be ingested.
Primary outcomes
- Change in white adipose tissue dietary fatty acid (DFA) trapping and partitioning (measured after liquid meal at Baseline (A0 +A1), at Day 12 (B0) and at Week 52 (C0))
- Change in lean organ (liver, heart and muscle) DFA uptake and partitioning (measured after liquid meal at Baseline (A0 +A1), at Day 12 (B0) and at Week 52 (C0))
- Change in liver non-esterified fatty acid (NEFA) uptake, oxidation, esterification and secretion into very low-density lipoprotein (VLDL). (measured before and after liquid meal at Baseline (A0), at Day 12 (B0) and at Week 52 (C0))
- Change in Endogenous Glucose production and meal glucose systemic flux (measured before and after liquid meal at Baseline (A0 +A1), at Day 12 (B0) and at Week 52 (C0))
- Change in cardiac non-esterified fatty acid (NEFA) uptake, oxidation and esterification (measured before and after liquid meal at Baseline (A0), at Day 12 (B0) and at Week 52 (C0))
Eligibility information
Inclusion Criteria:
* Aged 18 to 65
* BMI 35 kg/m2
* Diagnosed T2D - according to Diabetes Canada diagnostics criteria.
* Diagnosed non-T2D - according to Diabetes Canada diagnostics criteria.
* Women with a negative serum pregnancy test.
Exclusion Criteria:
* Treatment with an oral contraceptive;
* Treatment with fibrate, thiazolidinedione, insulin, or beta-blocker, drugs that affect metabolism and cannot be stopped temporarily or which have long-lasting effects;
* Presence of overt cardiovascular disease, liver or renal failure or other uncontrolled medical conditions;
* Any other contraindication to surgery or to temporarily suspending current medications for diabetes, lipids or hypertension;
* Smoking or consumption of more than 2 alcoholic beverages per day;
* Any contraindication to MRI;
* A Diabetes Remission (DiaRem) score \>8 (low probability of T2D remission);
* Having participated to a research study with exposure to radiation in the last two years before the start of the study;
* Pregnant or breastfeeding women;
* Patients weighing more than 200 kg to respect the weight and gantry limit of our MRI and PET/CT scanners.
* Being allergic to eggs
Study locations
- centre de recherche du CHUS, Sherbrooke, Quebec J1H 5N4 Canada
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.